OPKO Health, Inc. (NASDAQ:OPK) CEO Purchases $1,112,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPKGet Rating) CEO Phillip Md Et Al Frost acquired 400,000 shares of the firm’s stock in a transaction on Tuesday, May 10th. The stock was purchased at an average cost of $2.78 per share, for a total transaction of $1,112,000.00. Following the completion of the acquisition, the chief executive officer now owns 195,156,694 shares in the company, valued at $542,535,609.32. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, March 14th, Phillip Md Et Al Frost bought 35,000 shares of OPKO Health stock. The shares were bought at an average price of $3.04 per share, with a total value of $106,400.00.
  • On Friday, March 11th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were bought at an average price of $3.13 per share, with a total value of $313,000.00.
  • On Monday, February 28th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were bought at an average price of $3.11 per share, with a total value of $311,000.00.
  • On Friday, February 25th, Phillip Md Et Al Frost bought 750,000 shares of OPKO Health stock. The shares were bought at an average price of $3.09 per share, with a total value of $2,317,500.00.
  • On Monday, February 14th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were acquired at an average price of $3.04 per share, with a total value of $304,000.00.

NASDAQ OPK opened at $2.93 on Wednesday. The business has a 50 day simple moving average of $3.24 and a 200 day simple moving average of $3.68. OPKO Health, Inc. has a one year low of $2.43 and a one year high of $5.25. The stock has a market capitalization of $2.00 billion, a P/E ratio of -58.59 and a beta of 1.88. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.49 and a quick ratio of 2.23.

OPKO Health (NASDAQ:OPKGet Rating) last released its earnings results on Monday, May 9th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). OPKO Health had a negative return on equity of 1.75% and a negative net margin of 1.70%. The business had revenue of $329.20 million for the quarter, compared to analyst estimates of $331.45 million. During the same period in the prior year, the business earned $0.05 EPS. The company’s revenue for the quarter was down 39.6% on a year-over-year basis. Equities analysts expect that OPKO Health, Inc. will post -0.09 earnings per share for the current year.

OPK has been the subject of several research reports. StockNews.com initiated coverage on OPKO Health in a research report on Thursday, March 31st. They issued a “sell” rating for the company. Barrington Research downgraded OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Monday, January 24th. Piper Sandler dropped their target price on OPKO Health from $6.00 to $5.00 in a research report on Tuesday. Zacks Investment Research downgraded OPKO Health from a “buy” rating to a “hold” rating and set a $6.00 target price for the company. in a research report on Monday, January 24th. Finally, TheStreet downgraded OPKO Health from a “c” rating to a “d+” rating in a research report on Friday, February 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $6.00.

Institutional investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. grew its stake in OPKO Health by 5.2% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 58,060 shares of the biotechnology company’s stock worth $212,000 after buying an additional 2,854 shares in the last quarter. CIBC Asset Management Inc raised its holdings in OPKO Health by 11.4% during the 3rd quarter. CIBC Asset Management Inc now owns 28,189 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 2,883 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its position in OPKO Health by 19.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 19,200 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 3,100 shares during the period. UBS Asset Management Americas Inc. increased its position in OPKO Health by 1.1% during the 3rd quarter. UBS Asset Management Americas Inc. now owns 431,092 shares of the biotechnology company’s stock valued at $1,573,000 after purchasing an additional 4,577 shares during the period. Finally, Raymond James & Associates increased its position in OPKO Health by 6.2% during the 3rd quarter. Raymond James & Associates now owns 79,986 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 4,672 shares during the period. Institutional investors and hedge funds own 27.83% of the company’s stock.

About OPKO Health (Get Rating)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

See Also

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.